Active, not recruitingNCT04860765

COMPASSION S3 Post-Approval Study

Edwards LifesciencesMultiple US sitesView on ClinicalTrials.gov

AI Description

This study will monitor device performance and outcomes of the SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted surgical valve in the pulmonic position with a clinical indication for intervention.

Report inaccurate information

Who can join
child, adult, older adult
Participants
150
Expected completion
2030-08
Funded by
industry

Conditions studied

Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Degeneration, Pulmonary Valve Insufficiency, Pulmonary Valve; Obstruction

What is being tested

  • DEVICE: SAPIEN 3 THV

What it measures

  • Device Success, Defined as a composite of: * Single THV implanted in the desired location * Right ventricle to pulmonary artery peak-to-peak gradient \< 35 mmHg post-implantation * Less than moderate PR by discharge TTE * Free of explant at 24 hours post-implantation, Discharge, expected to be within 1-5 days post-procedure

Centers Participating

These centers are participating in this study. Reach out to them directly to learn more.

Data Sources and Methodology

Registry entry updated 2026-02-03

Deciding whether to join a study is your choice, and you can ask a study team questions before you decide anything.

If you would rather we did it with you, call us on (656) 206-4686.